Description
Anti-IL-5 Antibody, Non-Fucosylated (BioBet-018ZP) is a human monoclonal IgG antibody against IL-5. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Severe Eosinophilic Asthma
Severe nasal polyposis
Adult patients with eosinophilic granulomatosis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IL-5 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IL5
Full Name
interleukin 5
Background
This gene encodes a cytokine that acts as a growth and differentiation factor for both B cells and eosinophils. The encoded cytokine plays a major role in the regulation of eosinophil formation, maturation, recruitment and survival. The increased production of this cytokine may be related to pathogenesis of eosinophil-dependent inflammatory diseases. This cytokine functions by binding to its receptor, which is a heterodimer, whose beta subunit is shared with the receptors for interleukine 3 (IL3) and colony stimulating factor 2 (CSF2/GM-CSF). This gene is located on chromosome 5 within a cytokine gene cluster which includes interleukin 4 (IL4), interleukin 13 (IL13), and CSF2 . This gene, IL4, and IL13 may be regulated coordinately by long-range regulatory elements spread over 120 kilobases on chromosome 5q31
Alternative Names
EDF; TRF; IL-5
Gene ID
3567
UniProt ID
P05113
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with IL5 include Pulmonary Eosinophilia and Chronic Eosinophilic Pneumonia.
Related Pathways
Its related pathways are RET signaling and Signaling by GPCR.
Function
Factor that induces terminal differentiation of late-developing B-cells to immunoglobulin secreting cells.
Post-translational modifications
1. Glycosylation at Thr22 and Asn47 2. Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-018ZP
Description
Mepolizumab is a humanized monoclonal antibody that specifically recognizes and blocks interleukin 5 (IL-5).
Antibody Indication
Severe Eosinophilic Asthma
Severe nasal polyposis
Adult patients with eosinophilic granulomatosis
Severe Eosinophilic Asthma
Severe nasal polyposis
Adult patients with eosinophilic granulomatosis
